Patent: 9,968,606
✉ Email this page to a colleague
Summary for Patent: 9,968,606
Title: | Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof |
Abstract: | The invention provides novel chemical compounds useful for treating cancer or a related disease or disorder thereof, and pharmaceutical composition and methods of preparation and use thereof. |
Inventor(s): | Huang; Chaoran (Auburndale, MA), Cheng; Changfu (Northborough, MA) |
Assignee: | NeuForm Pharmaceuticals, Inc. (Auburndale, MA) |
Application Number: | 15/599,415 |
Patent Claims: | see list of patent claims |
Details for Patent 9,968,606
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | 02/26/2004 | ⤷ Try a Trial | 2035-12-27 |
Eli Lilly And Company | CYRAMZA | ramucirumab | Injection | 125477 | 04/21/2014 | ⤷ Try a Trial | 2035-12-27 |
Merck Sharp & Dohme Corp. | KEYTRUDA | pembrolizumab | For Injection | 125514 | 09/04/2014 | ⤷ Try a Trial | 2035-12-27 |
Merck Sharp & Dohme Corp. | KEYTRUDA | pembrolizumab | Injection | 125514 | 01/15/2015 | ⤷ Try a Trial | 2035-12-27 |
Eli Lilly And Company | PORTRAZZA | necitumumab | Injection | 125547 | 11/24/2015 | ⤷ Try a Trial | 2035-12-27 |
Bristol-myers Squibb Company | OPDIVO | nivolumab | Injection | 125554 | 12/22/2014 | ⤷ Try a Trial | 2035-12-27 |
Bristol-myers Squibb Company | OPDIVO | nivolumab | Injection | 125554 | 10/04/2017 | ⤷ Try a Trial | 2035-12-27 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |